| NCT ID | NCT05324553 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-04-06 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-04-06 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study goal is to collect tumor specimens that may inform cancer biology to eventually improve outcomes for patients with cancer. This proposal represents a highly collaborative effort to support cancer research with the goal of developing novel therapeutic strategies using patient derived preclinical models. This study is being done to collect samples of tumor tissues, matched normal tissue when possible, and approximately 50 mL of blood.
Eligibility Criteria
Inclusion Criteria: * 18 years of age and older * Patient is a good medical candidate for a standard of care or research biopsy or surgical procedure to obtain tissue Exclusion Criteria: * Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent * Institutionalized or incarcerated patients * Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use * Biopsy must not be considered more than minimal risk to the patient. * Have a contraindication to percutaneous biopsy including: 1. Significant coagulopathy that cannot be adequately corrected. 2. Severely compromised cardiopulmonary function or hemodynamic instability. 3. Lack of a safe pathway to the lesion per the interventional radiologist. 4. Inability of the patient to cooperate with, or to be positioned for, the procedure.
Contact & Investigator
Aaron S. Mansfield, M.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT05324553 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05324553 currently recruiting?
Yes, NCT05324553 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT05324553 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT05324553 clinical trial?
NCT05324553 is sponsored by Mayo Clinic. The principal investigator is Aaron S. Mansfield, M.D. at Mayo Clinic. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.